(KSB3) KSB SE & Co. KGaA - Overview
Stock: Pumps, Valves, Service
Dividends
| Dividend Yield | 3.41% |
| Yield on Cost 5y | 13.17% |
| Yield CAGR 5y | 58.31% |
| Payout Consistency | 84.5% |
| Payout Ratio | 81.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.0% |
| Relative Tail Risk | -5.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.94 |
| Alpha | 72.76 |
| Character TTM | |
|---|---|
| Beta | 0.034 |
| Beta Downside | 0.194 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.00% |
| CAGR/Max DD | 2.56 |
Description: KSB3 KSB SE & Co. KGaA January 25, 2026
KSB SE & Co. KGaA (XETRA:KSB3) manufactures and supplies pumps, valves, and related services worldwide through three operating segments: Pumps, Valves, and KSB SupremeServ, which provides installation, commissioning, maintenance and spare-parts support for its hardware. Its product portfolio serves energy and mining, water management, building services, petrochemicals/chemicals, and general industry customers.
In FY 2025 the company reported €3.6 billion in revenue, a 5 % YoY increase driven primarily by higher order intake in the water-infrastructure market. Adjusted EBIT margin improved to 12.8 % from 11.5 % in FY 2024, reflecting better pricing power and cost-efficiency initiatives. The order backlog at year-end stood at €1.2 billion, equivalent to 3.3 × annual sales, indicating a solid pipeline for the next 12-18 months.
Key macro drivers include accelerating global investment in water-treatment and renewable-energy infrastructure, which together account for roughly €1.2 trillion of projected capex through 2028, and a modest but sustained rise in industrial automation spending that benefits KSB’s valve-actuator and pump-control offerings. Conversely, a slowdown in petrochemical capital projects in Asia could temper demand in that segment.
For a deeper quantitative assessment, you may wish to explore KSB’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 266.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 8.57 > 1.0 |
| NWC/Revenue: 15.64% < 20% (prev 31.77%; Δ -16.13% < -1%) |
| CFO/TA 0.19 > 3% & CFO 528.6m > Net Income 266.1m |
| Net Debt (-234.4m) to EBITDA (816.3m): -0.29 < 3 |
| Current Ratio: 1.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.75m) vs 12m ago 0.02% < -2% |
| Gross Margin: 31.18% > 18% (prev 0.21%; Δ 3096 % > 0.5%) |
| Asset Turnover: 220.8% > 50% (prev 110.5%; Δ 110.3% > 0%) |
| Interest Coverage Ratio: 20.35 > 6 (EBITDA TTM 816.3m / Interest Expense TTM 30.7m) |
Altman Z'' 5.94
| A: 0.33 (Total Current Assets 1.86b - Total Current Liabilities 944.7m) / Total Assets 2.76b |
| B: 0.45 (Retained Earnings 1.24b / Total Assets 2.76b) |
| C: 0.24 (EBIT TTM 625.1m / Avg Total Assets 2.66b) |
| D: 0.68 (Book Value of Equity 1.00b / Total Liabilities 1.48b) |
| Altman-Z'' Score: 5.94 = AAA |
Beneish M -2.92
| DSRI: 0.49 (Receivables 724.1m/715.1m, Revenue 5.86b/2.81b) |
| GMI: 0.68 (GM 31.18% / 21.35%) |
| AQI: 1.22 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 2.08 (Revenue 5.86b / 2.81b) |
| TATA: -0.09 (NI 266.1m - CFO 528.6m) / TA 2.76b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of KSB3 shares?
Over the past week, the price has changed by +2.73%, over one month by +8.13%, over three months by +19.20% and over the past year by +77.26%.
Is KSB3 a buy, sell or hold?
What are the forecasts/targets for the KSB3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1167.7 | 3.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1702 | 50.6% |
KSB3 Fundamental Data Overview February 08, 2026
P/E Trailing = 16.6393
P/S = 0.6569
P/B = 1.8298
Revenue TTM = 5.86b EUR
EBIT TTM = 625.1m EUR
EBITDA TTM = 816.3m EUR
Long Term Debt = 100.0k EUR (from longTermDebt, last quarter)
Short Term Debt = 21.2m EUR (from shortTermDebt, last quarter)
Debt = 55.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -234.4m EUR (from netDebt column, last quarter)
Enterprise Value = 1.73b EUR (1.97b + Debt 55.7m - CCE 290.1m)
Interest Coverage Ratio = 20.35 (Ebit TTM 625.1m / Interest Expense TTM 30.7m)
EV/FCF = 6.29x (Enterprise Value 1.73b / FCF TTM 275.4m)
FCF Yield = 15.90% (FCF TTM 275.4m / Enterprise Value 1.73b)
FCF Margin = 4.70% (FCF TTM 275.4m / Revenue TTM 5.86b)
Net Margin = 4.54% (Net Income TTM 266.1m / Revenue TTM 5.86b)
Gross Margin = 31.18% ((Revenue TTM 5.86b - Cost of Revenue TTM 4.04b) / Revenue TTM)
Gross Margin QoQ = 58.63% (prev 22.93%)
Tobins Q-Ratio = 0.63 (Enterprise Value 1.73b / Total Assets 2.76b)
Interest Expense / Debt = 8.44% (Interest Expense 4.70m / Debt 55.7m)
Taxrate = 33.56% (34.9m / 104.0m)
NOPAT = 415.4m (EBIT 625.1m * (1 - 33.56%))
Current Ratio = 1.97 (Total Current Assets 1.86b / Total Current Liabilities 944.7m)
Debt / Equity = 0.05 (Debt 55.7m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = -0.29 (Net Debt -234.4m / EBITDA 816.3m)
Debt / FCF = -0.85 (Net Debt -234.4m / FCF TTM 275.4m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.02% (Net Income 266.1m / Total Assets 2.76b)
RoE = 25.36% (Net Income TTM 266.1m / Total Stockholder Equity 1.05b)
RoCE = 59.56% (EBIT 625.1m / Capital Employed (Equity 1.05b + L.T.Debt 100.0k))
RoIC = 39.33% (NOPAT 415.4m / Invested Capital 1.06b)
WACC = 6.03% (E(1.97b)/V(2.02b) * Re(6.04%) + D(55.7m)/V(2.02b) * Rd(8.44%) * (1-Tc(0.34)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.01%
[DCF Debug] Terminal Value 87.98% ; FCFF base≈179.4m ; Y1≈221.4m ; Y5≈377.0m
Fair Price DCF = 12.4k (EV 10.52b - Net Debt -234.4m = Equity 10.75b / Shares 864.7k; r=6.03% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -30.96 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.87 | Revenue CAGR: 11.01% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=93.47 | Chg30d=-0.215 | Revisions Net=-1 | Growth EPS=+12.6% | Growth Revenue=+6.6%